President Trump signed an executive order imposing a 100% ad valorem tariff on imported brand-name patented pharmaceuticals and associated ingredients under Section 232, with exemptions and country-specific carveouts. The policy includes potential reductions for companies with plans to manufacture in the US and reduced rates for certain regions, while generics and orphan drugs are excluded. Trade terms are being tied to “Most Favored Nation” arrangements, and the administration’s statements frame the policy as both a national security measure and a lever to reduce import reliance. The pharmaceutical industry response in the excerpt emphasizes cost pressure and the risk of jeopardizing investment plans and manufacturing expansion. In parallel, reporting indicates the administration is negotiating drug-pricing deals with smaller companies as a route to avoid tariffs or pricing policies, suggesting a bifurcated strategy: tariff threat plus confidential price agreements. Overall, the immediate biotech-relevant implication is pricing and supply-chain uncertainty for brand-name products without MFN or US-manufacturing commitments.